| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| Net revenue | 187,797 | 181,330 | 167,824 | 164,502 |
| Cost of revenue | 107,351 | 104,072 | 92,944 | 92,008 |
| Gross profit | 80,446 | 77,258 | 74,880 | 72,494 |
| General and administrative | 69,874 | 71,747 | 66,969 | 63,328 |
| Restructuring charges | - | - | 1,009 | 1,544 |
| Research and development | 8,694 | 9,023 | 7,684 | 7,886 |
| Sales and marketing | 21,806 | 24,075 | 20,415 | 21,677 |
| Restructuring charges | 0 | 0 | - | - |
| Impairment charges (note 5) | 7,086 | 20,041 | - | - |
| Total operating expenses | 107,460 | 124,886 | 96,077 | 94,435 |
| Loss from operations | -27,014 | -47,628 | -21,197 | -21,941 |
| Interest income | 1,563 | 2,263 | 4,673 | 4,592 |
| Interest expense | 603 | 933 | 1,642 | 1,666 |
| Other expense (income), net | -335 | 482 | 317 | -2 |
| Loss before taxes | -26,389 | -45,816 | -17,849 | -19,017 |
| Income tax expense (benefit) | 740 | -724 | -150 | -375 |
| Net loss | -27,129 | -45,092 | -17,699 | -18,642 |
| Basic (in shares) | 128,415,000 | 127,949,000 | 126,953,000 | 126,405,000 |
| Diluted (in shares) | 128,415,000 | 127,949,000 | 126,953,000 | 126,405,000 |
NEOGENOMICS INC (NEO)
NEOGENOMICS INC (NEO)